文献速递胸部肿瘤

纳武利尤单抗治疗晚期非小细胞肺癌患者的早期免疫相关不良事件与结局的关联:一项前瞻性队列研究

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.
PubMed 文献 · J Thorac Oncol · 2017-09-20

该前瞻性队列研究纳入2016年1月至12月接受纳武利尤单抗治疗的晚期非小细胞肺癌患者43例,评估用药后2至6周内出现的免疫相关不良事件(irAEs)与临床结局的关联。结果显示,出现irAEs的患者客观缓解率和疾病控制率更高,中位无进展生存期显著更长。结论认为早期irAEs与免疫治疗后的更好结局相关,但需进一步研究阐明机制。

要点

  • 出现irAEs的患者客观缓解率为37%,未出现者为17%,差异未达统计学显著(p=0.17)。
  • 出现irAEs的患者疾病控制率为74%,未出现者为29%,差异有统计学意义(p<0.01)。
  • 出现irAEs的患者中位无进展生存期为6.4个月,未出现者为1.5个月(p=0.01)。

核心结论

  • 早期免疫相关不良事件与纳武利尤单抗治疗晚期非小细胞肺癌后的更好结局相关。
  • 作者利用早期irAEs预测纳武利尤单抗的疗效反应,并指出需进一步研究阐明这些关联的机制。

研究设计与样本

  • 前瞻性队列研究,纳入2016年1月至12月接受纳武利尤单抗治疗的晚期非小细胞肺癌患者43例。
  • 评估纳武利尤单抗治疗开始后2至6周内出现的irAEs与临床结局的关联,irAEs由至少三名独立医疗专业人员评估。

主要发现

  • 共43例患者入组,其中19例在纳武利尤单抗治疗开始后2周出现irAEs;常见irAEs包括皮疹、发热和腹泻。
  • 程序性细胞死亡配体1阳性肿瘤细胞表达在出现与未出现irAEs的患者间无显著差异。
  • 出现irAEs的患者客观缓解率为37%,未出现者为17%(p=0.17);疾病控制率分别为74%和29%(p<0.01)。
  • 出现irAEs的患者中位无进展生存期为6.4个月(95%CI:2.5-未达到),未出现者为1.5个月(95%CI:1.2-2.3)(p=0.01)。
  • 上述发现在纳武利尤单抗治疗开始后6周评估irAEs时与2周时的结果相当。

局限性

  • 原文指出需进一步研究以阐明这些关联的机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy. METHODS: We conducted a prospective cohort study of patients with advanced NSCLC who were treated with nivolumab between January and December 2016. The association between clinical outcome and irAEs 2 to 6 weeks after commencement of nivolumab treatment was investigated. IrAEs were assessed by at least three independent medical professionals. RESULTS: A total of 43 patients were enrolled, including 19 patients with irAEs 2 weeks after commencement of nivolumab treatment. Common irAEs included rash, pyrexia, and diarrhea. Programmed cell death ligand 1-positive tumor cell expression was not significantly different between patients with and without irAEs. The objective response and disease control rates were higher in patients with irAEs than in those without irAEs (37% versus 17% and 74% versus 29% [p = 0.17 and p < 0.01], respectively]). Patients with irAEs were associated with a significantly longer median progression-free survival than those without (6.4 months [95% confidence interval: 2.5-not reached] versus 1.5 months [95% confidence interval: 1.2-2.3] [p = 0.01]). These findings were comparable to those for patients with and without irAEs 6 weeks after commencement of nivolumab treatment. CONCLUSIONS: Early irAEs are associated with a better outcome after treatment with immunotherapy. We predicted responses to nivolumab by using early irAEs. Further research is needed to elucidate the mechanisms of these associations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Teraoka S, Fujimoto D, Morimoto T, et al. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol. 2017. PMID: 28939128. doi:10.1016/j.jtho.2017.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。